Personalized Cancer Vaccines Market Report 2026

Personalized Cancer Vaccines Market Overview

• Personalized Cancer Vaccines market size has reached to $256.65 billion in 2025 • Expected to grow to $350.3 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: Increasing Cancer Incidence Accelerates Demand For Targeted Immunotherapies • Market Trend: Innovative Therapies Target Specific Cancer Mutations For Enhanced Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Personalized Cancer Vaccines Market?

Personalized cancer vaccines refer to treatments tailored to an individual's unique tumor profile, aiming to stimulate their immune system to target and destroy cancer cells. They improve the body's ability to recognize and fight specific cancer types, potentially enhancing treatment efficacy and reducing recurrence. The main types of personalized cancer vaccines are preventive cancer vaccines and therapeutic cancer vaccines. Preventive cancer vaccines are designed to protect against infections or conditions that may lead to cancer. It is used to treat various cancer types, including lung cancer, breast cancer, colorectal cancer, leukemia, prostate cancer, cervical cancer, and glioblastoma, through different mechanisms of action, including tumor-associated antigens (TAAS), tumor-specific antigens (TSAS), somatic mutations in cancer pharmacogenomics, pharmacogenomics towards genomic polymorphism, and others. It is provided through varying routes of administration, which include injectables and others in different end uses, such as hospitals, clinics, and others.

What Is The Personalized Cancer Vaccines Market Growth Forecast?

The personalized cancer vaccines market size is expected to see strong growth in the next few years. It will grow to $350.3 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to expansion of personalized medicine adoption, increasing cancer incidence rates, progress in neoantigen discovery, rising collaboration between biotech firms, supportive regulatory frameworks. Major trends in the forecast period include rising focus on personalized immunotherapy, increasing use of genomic tumor profiling, expansion of therapeutic cancer vaccines, growing integration with precision oncology, higher clinical trial activity in cancer vaccines.

Global Personalized Cancer Vaccines Market Segmentation

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines 2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma 3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action 4) By Route Of Administration: Injectables, Other Routes Of Administration 5) By End Use: Hospitals, Clinic, Other End Users Subsegments: 1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines 2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

What Is The Driver Of The Personalized Cancer Vaccines Market?

The increasing prevalence of cancer is expected to propel the growth of the personalized cancer vaccine market going forward. Cancer refers to a group of diseases characterized by uncontrolled cell growth that can invade surrounding tissues and spread to other parts of the body. The increasing prevalence of cancer is driven by aging populations, lifestyle changes, environmental exposures, and improved diagnostic capabilities. The personalized cancer vaccine market supports cancer care by delivering vaccines tailored to patient-specific tumor antigens, strengthening the immune system’s ability to identify and eliminate cancer cells. For instance, in July 2024, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, cancer diagnoses in Australia rose from 160,570 cases in 2022 to 164,694 cases in 2023, indicating a significant year-over-year increase. Therefore, the increasing prevalence of cancer is driving the growth of the personalized cancer vaccine industry.

Key Players In The Global Personalized Cancer Vaccines Market

Major companies operating in the personalized cancer vaccines market are Moderna Inc., CureVac AG, BioNTech SE, Genentech Inc., Merck & Co. Inc., GlaxoSmithKline plc, Achilles Therapeutics Plc, Evaxion Biotech AS, Geneos Therapeutics Inc., ISA Pharmaceuticals BV, VAXIMM GmbH, EpiVax Therapeutics Inc., Personalis Inc., Catalent Inc., Gritstone bio Inc., Neon Therapeutics Inc., Nouscom AG, Vaccitech plc, Agenus Inc., Transgene SA

Global Personalized Cancer Vaccines Market Trends and Insights

Major companies operating in the personalized cancer vaccine market are focusing on developing advanced therapeutic solutions, such as personalized immunotherapy designed to target patient-specific tumor mutations, to enhance treatment precision and improve clinical outcomes. Personalized immunotherapy refers to customized cancer treatments that use a patient’s own genetic and tumor mutation profile often delivered through dendritic cell–based vaccines or neoantigen-targeted platforms to activate a tailored immune response against malignant cells. For instance, in August 2024, UCLA Health, a US-based healthcare organization, launched a first-of-its-kind clinical trial evaluating a personalized cancer vaccine that targets the H3 G34 mutation in diffuse hemispheric gliomas, using dendritic cells to stimulate immunity against the RNA disruptions caused by this aggressive mutation, offering a promising therapeutic option for adolescents and young adults who typically have limited treatment choices and poor survival rates.

What Are Latest Mergers And Acquisitions In The Personalized Cancer Vaccines Market?

In June 2025, BioNTech SE, a Germany‑based biotechnology company, acquired CureVac N.V., a for an undisclosed amount. With this acquisition, BioNTech aims to strengthen its research, development, manufacturing, and commercialization of mRNA‑based cancer immunotherapy, deepening its oncology strategy. CureVac N.V. is a Germany‑based Company that developing personalized cancer vaccines.

Regional Insights

North America was the largest region in the personalized cancer vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Personalized Cancer Vaccines Market?

The personalized cancer vaccines market consists of sales of patient-specific vaccines, neoantigen-based therapies, dendritic cell-based vaccines and peptide-based immunotherapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Personalized Cancer Vaccines Market Report 2026?

The personalized cancer vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the personalized cancer vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.